{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:39:40Z","timestamp":1792798780251,"version":"4.5.0"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002713","name":"Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}],"id":[{"id":"10.13039\/501100002713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01570-3","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T12:15:57Z","timestamp":1755778557000},"page":"1043-1061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tackling tumor hypoxia: advances in breaking the oncogenic HIF-1\u03b1\u2013p300\/CBP alliance"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-9564","authenticated-orcid":false,"given":"Emadeldin M.","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally Mostafa","family":"Khadrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris F. Aba","family":"Alkhayl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al Mokhtar","family":"Lamsabhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"13","key":"1570_CR1","doi-asserted-by":"publisher","first-page":"8877","DOI":"10.1021\/jacs.3c10508","volume":"146","author":"AT Ball","year":"2024","unstructured":"Ball AT et al (2024) Identification and development of cyclic peptide inhibitors of hypoxia inducible factors 1 and 2 that disrupt hypoxia-response signaling in cancer cells. J Am Chem Soc 146(13):8877\u20138886","journal-title":"J Am Chem Soc"},{"issue":"1","key":"1570_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s10020-025-01149-x","volume":"31","author":"D Benak","year":"2025","unstructured":"Benak D et al (2025) Epitranscriptomic regulation of HIF-1: bidirectional regulatory pathways. Mol Med 31(1):105","journal-title":"Mol Med"},{"issue":"1","key":"1570_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s11658-024-00682-7","volume":"30","author":"J Zhang","year":"2025","unstructured":"Zhang J et al (2025) Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer. Cell Mol Biol Lett 30(1):2","journal-title":"Cell Mol Biol Lett"},{"key":"1570_CR4","first-page":"21","volume-title":"Adaptation under stressful environments through biological adjustments and interventions","author":"A Krishnan","year":"2024","unstructured":"Krishnan A, Ansari HK (2024) Molecular basis of response to hypoxia. Adaptation under stressful environments through biological adjustments and interventions. Springer, pp 21\u201340"},{"key":"1570_CR5","doi-asserted-by":"crossref","unstructured":"Strocchi S et al (2022) The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation. Oncogene 41(29):3665\u20133679","DOI":"10.1038\/s41388-022-02378-8"},{"key":"1570_CR6","doi-asserted-by":"crossref","unstructured":"Focaccio A et al (2024) A spotlight on the role of copper in the epithelial to mesenchymal transition. Life Sci 354:122972","DOI":"10.1016\/j.lfs.2024.122972"},{"key":"1570_CR7","doi-asserted-by":"crossref","unstructured":"Ubaid S et al (2024) Targeting HIF-1\u03b1 in sickle cell disease and cancer: unraveling therapeutic opportunities and risks. Expert Opin Ther Targets 28(5):357\u2013373","DOI":"10.1080\/14728222.2024.2367640"},{"key":"1570_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.abb.2015.04.012","volume":"576","author":"G Machado-Oliveira","year":"2015","unstructured":"Machado-Oliveira G et al (2015) FBXL5 modulates HIF-1\u03b1 transcriptional activity by degradation of CITED2. Arch Biochem Biophys 576:61\u201372","journal-title":"Arch Biochem Biophys"},{"key":"1570_CR9","doi-asserted-by":"crossref","unstructured":"Tipoe GL et al (2006) Expression and functions of vasoactive substances regulated by hypoxia-inducible factor-1 in chronic hypoxemia. Cardiovasc Hematol Agents Med Chem (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents) 4(3):199\u2013218","DOI":"10.2174\/187152506777698290"},{"issue":"8","key":"1570_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00018-023-04852-2","volume":"80","author":"E Stampone","year":"2023","unstructured":"Stampone E et al (2023) Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy. Cell Mol Life Sci 80(8):220","journal-title":"Cell Mol Life Sci"},{"key":"1570_CR11","doi-asserted-by":"publisher","first-page":"1403915","DOI":"10.3389\/fcimb.2024.1403915","volume":"14","author":"KK Ting","year":"2024","unstructured":"Ting KK (2024) Revisiting the role of hypoxia-inducible factors and nuclear factor erythroid 2-related factor 2 in regulating macrophage inflammation and metabolism. Front Cell Infect Microbiol 14:1403915","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"1570_CR12","doi-asserted-by":"publisher","first-page":"e2309957121","DOI":"10.1073\/pnas.2309957121","volume":"121","author":"J Ma","year":"2024","unstructured":"Ma J et al (2024) Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment. Proc Natl Acad Sci 121(10):e2309957121","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"1570_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/07357907.2024.2361295","volume":"42","author":"FH Al-Ostoot","year":"2024","unstructured":"Al-Ostoot FH, Salah S, Khanum SA (2024) An overview of cancer biology, pathophysiological development and it\u2019s treatment modalities: current challenges of cancer anti-angiogenic therapy. Cancer Invest 42(7):559\u2013604","journal-title":"Cancer Invest"},{"issue":"17","key":"1570_CR14","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/cancers16172975","volume":"16","author":"MA Rahman","year":"2024","unstructured":"Rahman MA, Ali MM (2024) Recent treatment strategies and molecular pathways in resistance mechanisms of antiangiogenic therapies in glioblastoma. Cancers 16(17):2975","journal-title":"Cancers"},{"key":"1570_CR15","first-page":"103","volume-title":"Nanotechnology based strategies for cancer immunotherapy: concepts, design, and clinical applications","author":"S Chenchula","year":"2025","unstructured":"Chenchula S et al (2025) Combination therapies for the management of cancer immunotherapy. Nanotechnology based strategies for cancer immunotherapy: concepts, design, and clinical applications. Springer, pp 103\u2013144"},{"issue":"12","key":"1570_CR16","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.1021\/acs.jmedchem.8b01596","volume":"62","author":"Z Li","year":"2019","unstructured":"Li Z, You Q, Zhang X (2019) Small-molecule modulators of the hypoxia-inducible factor pathway: development and therapeutic applications. J Med Chem 62(12):5725\u20135749","journal-title":"J Med Chem"},{"key":"1570_CR17","doi-asserted-by":"publisher","first-page":"116527","DOI":"10.1016\/j.ejmech.2024.116527","volume":"274","author":"SM Hefny","year":"2024","unstructured":"Hefny SM et al (2024) A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments. Eur J Med Chem 274:116527","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1570_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41392-024-02083-w","volume":"10","author":"Y Zhang","year":"2025","unstructured":"Zhang Y et al (2025) Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use. Signal Transduct Target Ther 10(1):44","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"1570_CR19","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.3390\/molecules29194524","volume":"29","author":"D Masci","year":"2024","unstructured":"Masci D et al (2024) Targeting CBP and p300: emerging anticancer agents. Molecules 29(19):4524","journal-title":"Molecules"},{"key":"1570_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41585-024-00991-8","volume":"22","author":"V Const\u00e2ncio","year":"2025","unstructured":"Const\u00e2ncio V et al (2025) Prostate cancer epigenetics\u2014from pathophysiology to clinical application. Nat Rev Urol 22:447\u2013469","journal-title":"Nat Rev Urol"},{"issue":"12","key":"1570_CR21","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1080\/17425247.2024.2429702","volume":"21","author":"S Khot","year":"2024","unstructured":"Khot S et al (2024) Innovative drug delivery strategies for targeting glioblastoma: overcoming the challenges of the tumor microenvironment. Expert Opin Drug Deliv 21(12):1837\u20131857","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"1570_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s13346-024-01669-9","volume":"15","author":"P Famta","year":"2025","unstructured":"Famta P et al (2025) Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation. Drug Deliv Transl Res 15(2):389\u2013406","journal-title":"Drug Deliv Transl Res"},{"key":"1570_CR23","doi-asserted-by":"publisher","first-page":"1513047","DOI":"10.3389\/fimmu.2024.1513047","volume":"15","author":"W Wang","year":"2025","unstructured":"Wang W et al (2025) Lactate-induced protein lactylation in cancer: functions, biomarkers and immunotherapy strategies. Front Immunol 15:1513047","journal-title":"Front Immunol"},{"issue":"4","key":"1570_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/ph17040533","volume":"17","author":"D Danielpour","year":"2024","unstructured":"Danielpour D (2024) Advances and challenges in targeting tgf-\u03b2 isoforms for therapeutic intervention of cancer: a mechanism-based perspective. Pharmaceuticals 17(4):533","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1570_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/21541264.2024.2417475","volume":"16","author":"A McDermott","year":"2024","unstructured":"McDermott A, Tavassoli A (2024) Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discovery. Transcription 16(1):86\u2013117","journal-title":"Transcription"},{"key":"1570_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41556-025-01635-8","volume":"27","author":"Z Zong","year":"2025","unstructured":"Zong Z et al (2025) Emerging roles of lysine lactyltransferases and lactylation. Nat Cell Biol 27:563\u2013574","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1570_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2021.10.004","volume":"8","author":"SJ Cowman","year":"2022","unstructured":"Cowman SJ, Koh MY (2022) Revisiting the HIF switch in the tumor and its immune microenvironment. Trends Cancer 8(1):28\u201342","journal-title":"Trends Cancer"},{"issue":"1","key":"1570_CR28","doi-asserted-by":"publisher","first-page":"e000154","DOI":"10.1136\/bmjonc-2023-000154","volume":"3","author":"BM Ortmann","year":"2024","unstructured":"Ortmann BM (2024) Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ oncology 3(1):e000154","journal-title":"BMJ oncology"},{"issue":"1","key":"1570_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10555-023-10129-8","volume":"43","author":"SF Jawad","year":"2024","unstructured":"Jawad SF et al (2024) The strict regulation of HIF-1\u03b1 by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies. Cancer Metastasis Rev 43(1):5\u201327","journal-title":"Cancer Metastasis Rev"},{"issue":"14","key":"1570_CR30","doi-asserted-by":"publisher","first-page":"11580","DOI":"10.1021\/acs.jmedchem.4c00723","volume":"67","author":"Y Xiao","year":"2024","unstructured":"Xiao Y et al (2024) Targeted protein degradation: current and emerging approaches for E3 ligase deconvolution. J Med Chem 67(14):11580\u201311596","journal-title":"J Med Chem"},{"issue":"4","key":"1570_CR31","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.drudis.2021.10.020","volume":"27","author":"GA Holdgate","year":"2022","unstructured":"Holdgate GA et al (2022) Drug discovery for epigenetics targets. Drug Discov Today 27(4):1088\u20131098","journal-title":"Drug Discov Today"},{"issue":"1","key":"1570_CR32","doi-asserted-by":"publisher","first-page":"9614","DOI":"10.1038\/s41467-024-53981-0","volume":"15","author":"K Hyun","year":"2024","unstructured":"Hyun K et al (2024) The BAF complex enhances transcription through interaction with H3K56ac in the histone globular domain. Nat Commun 15(1):9614","journal-title":"Nat Commun"},{"issue":"1","key":"1570_CR33","doi-asserted-by":"publisher","first-page":"115213","DOI":"10.1016\/j.celrep.2024.115213","volume":"44","author":"RS Porter","year":"2025","unstructured":"Porter RS et al (2025) Coordinated neuron-specific splicing events restrict nucleosome engagement of the LSD1 histone demethylase complex. Cell Rep 44(1):115213","journal-title":"Cell Rep"},{"key":"1570_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41420-025-02491-z","volume":"11","author":"X Yang","year":"2025","unstructured":"Yang X et al (2025) Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment. Cell Death Discov 11:189","journal-title":"Cell Death Discov"},{"issue":"11","key":"1570_CR35","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.7150\/thno.73223","volume":"12","author":"Q Chen","year":"2022","unstructured":"Chen Q (2022) Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents. Theranostics 12(11):4935\u20134948","journal-title":"Theranostics"},{"issue":"8","key":"1570_CR36","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1073\/pnas.082117899","volume":"99","author":"SJ Freedman","year":"2002","unstructured":"Freedman SJ et al (2002) Structural basis for recruitment of CBP\/p300 by hypoxia-inducible factor-1\u03b1. Proc Natl Acad Sci 99(8):5367\u20135372","journal-title":"Proc Natl Acad Sci"},{"key":"1570_CR37","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s10695-024-01356-z","volume":"50","author":"Z Liang","year":"2024","unstructured":"Liang Z et al (2024) Molecular characterization and function of hif1a and fih1 in response to acute thermal stress in American shad (Alosa sapidissima). Fish Physiol Biochem 50:1563\u20131581","journal-title":"Fish Physiol Biochem"},{"issue":"2","key":"1570_CR38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1165\/rcmb.2022-0481OC","volume":"70","author":"N Wang","year":"2024","unstructured":"Wang N et al (2024) P300\/CBP regulates HIF-1\u2013Dependent sympathetic activation and hypertension by intermittent hypoxia. Am J Respir Cell Mol Biol 70(2):110\u2013118","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"1570_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/17501911.2024.2447807","volume":"17","author":"L Xu","year":"2025","unstructured":"Xu L, Xuan H, Shi X (2025) Dysregulation of the p300\/CBP histone acetyltransferases in human cancer. Epigenomics 17(3):193\u2013208","journal-title":"Epigenomics"},{"issue":"1","key":"1570_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/life14010020","volume":"14","author":"M Minisini","year":"2024","unstructured":"Minisini M et al (2024) Acetylation and phosphorylation in the regulation of hypoxia-inducible factor activities: additional options to modulate adaptations to changes in oxygen levels. Life 14(1):20","journal-title":"Life"},{"issue":"7","key":"1570_CR41","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.3390\/ijms12074705","volume":"12","author":"JI Perez-Perri","year":"2011","unstructured":"Perez-Perri JI, Acevedo JM, Wappner P (2011) Epigenetics: new questions on the response to hypoxia. Int J Mol Sci 12(7):4705\u20134721","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1570_CR42","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.31557\/APJCP.2024.25.4.1121","volume":"25","author":"S Pandey","year":"2024","unstructured":"Pandey S et al (2024) Regulation of hypoxia dependent reprogramming of cancer metabolism: Role of hif-1 and its potential therapeutic implications in leukemia. Asian Pacific J Cancer Prev: APJCP 25(4):1121","journal-title":"Asian Pacific J Cancer Prev: APJCP"},{"issue":"1","key":"1570_CR43","doi-asserted-by":"publisher","first-page":"e70145","DOI":"10.1002\/ctm2.70145","volume":"15","author":"C Wang","year":"2025","unstructured":"Wang C, Ma X (2025) The role of acetylation and deacetylation in cancer metabolism. Clin Transl Med 15(1):e70145","journal-title":"Clin Transl Med"},{"issue":"3","key":"1570_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/biom13030417","volume":"13","author":"Q Zeng","year":"2023","unstructured":"Zeng Q et al (2023) Effects of the acetyltransferase p300 on tumour regulation from the novel perspective of posttranslational protein modification. Biomolecules 13(3):417","journal-title":"Biomolecules"},{"key":"1570_CR45","doi-asserted-by":"publisher","first-page":"1495221","DOI":"10.3389\/fimmu.2024.1495221","volume":"15","author":"X Duan","year":"2024","unstructured":"Duan X (2024) The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications. Front Immunol 15:1495221","journal-title":"Front Immunol"},{"issue":"19","key":"1570_CR46","doi-asserted-by":"publisher","first-page":"10701","DOI":"10.3390\/ijms221910701","volume":"22","author":"J Korbecki","year":"2021","unstructured":"Korbecki J (2021) Chronic and cycling hypoxia: drivers of cancer chronic inflammation through HIF-1 and NF-\u03baB activation: a review of the molecular mechanisms. Int J Mol Sci 22(19):10701","journal-title":"Int J Mol Sci"},{"issue":"23","key":"1570_CR47","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1161\/CIRCULATIONAHA.121.057599","volume":"145","author":"R Chakraborty","year":"2022","unstructured":"Chakraborty R et al (2022) Histone acetyltransferases p300 and CBP coordinate distinct chromatin remodeling programs in vascular smooth muscle plasticity. Circulation 145(23):1720\u20131737","journal-title":"Circulation"},{"key":"1570_CR48","doi-asserted-by":"crossref","unstructured":"AS S et al (2024) p300\/CBP KATs are critical for maturation and differentiation of adult neural progenitors. ACS Chem Biol 19(11):2345\u20132358","DOI":"10.1021\/acschembio.4c00465"},{"issue":"6","key":"1570_CR49","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s43018-024-00761-w","volume":"5","author":"H Lawson","year":"2024","unstructured":"Lawson H et al (2024) The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1\u03b1 and compromises development and progression of acute myeloid leukemia. Nature cancer 5(6):916\u2013937","journal-title":"Nature cancer"},{"key":"1570_CR50","doi-asserted-by":"crossref","unstructured":"Gronkowska K, Robaszkiewicz A (2024) Genetic dysregulation of EP300 in cancers in light of cancer epigenome control\u2013perspectives of specific targeting of p300 proficient and deficient cancers. Mol Ther Oncol","DOI":"10.1016\/j.omton.2024.200871"},{"issue":"4","key":"1570_CR51","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/1389557516666160630124938","volume":"18","author":"J Wei","year":"2018","unstructured":"Wei J et al (2018) Recent advances in the discovery of HIF-1\u03b1-p300\/CBP inhibitors as anti-cancer agents. Mini Rev Med Chem 18(4):296\u2013309","journal-title":"Mini Rev Med Chem"},{"issue":"1","key":"1570_CR52","doi-asserted-by":"publisher","first-page":"2407223","DOI":"10.1155\/2022\/2407223","volume":"2022","author":"S Rani","year":"2022","unstructured":"Rani S et al (2022) Regulation of transactivation at C-TAD Domain of HIF-1\u03b1 by factor-inhibiting HIF-1\u03b1 (FIH-1): a potential target for therapeutic intervention in cancer. Oxid Med Cell Longev 2022(1):2407223","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"1570_CR53","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.bbr.2011.08.002","volume":"227","author":"LA Cunningham","year":"2012","unstructured":"Cunningham LA, Candelario K, Li L (2012) Roles for HIF-1\u03b1 in neural stem cell function and the regenerative response to stroke. Behav Brain Res 227(2):410\u2013417","journal-title":"Behav Brain Res"},{"issue":"9","key":"1570_CR54","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/cancers16091729","volume":"16","author":"PWT Lee","year":"2024","unstructured":"Lee PWT et al (2024) Hypoxia-inducible factor-dependent and independent mechanisms underlying chemoresistance of hypoxic cancer cells. Cancers 16(9):1729","journal-title":"Cancers"},{"key":"1570_CR55","doi-asserted-by":"crossref","unstructured":"Fiorini G, Schofield CJ (2024) Biochemistry of the hypoxia-inducible factor hydroxylases. Curr Opin Chem Biol 79:102428","DOI":"10.1016\/j.cbpa.2024.102428"},{"key":"1570_CR56","doi-asserted-by":"crossref","unstructured":"Albanese A et al (2020) The role of hypoxia-inducible factor post-translational modifications in regulating its localisation, stability, and activity. Int J Mol Sci 22(1):268","DOI":"10.3390\/ijms22010268"},{"key":"1570_CR57","doi-asserted-by":"crossref","unstructured":"He Q et al (2021) Biological functions and regulatory mechanisms of hypoxia-inducible factor-1\u03b1 in ischemic stroke. Front Immunol 12:801985","DOI":"10.3389\/fimmu.2021.801985"},{"key":"1570_CR58","unstructured":"Kyle HF (2015) Biophysical and structural characterisation of protein-protein interactions, HIF-1\u03b1\/p300 and eIF4E\/eIF4G to inform inhibitor rational design. University of Leeds"},{"key":"1570_CR59","doi-asserted-by":"crossref","unstructured":"Minisini M, Cricchi E, Brancolini C (2023) Acetylation and phosphorylation in the regulation of hypoxia-inducible factor activities: additional options to modulate adaptations to changes in oxygen levels. Life 14(1):20","DOI":"10.3390\/life14010020"},{"key":"1570_CR60","doi-asserted-by":"crossref","unstructured":"Liu Y et al (2024) ALKBH1 promotes HIF-1 \u03b1-mediated glycolysis by inhibiting N-glycosylation of LAMP2A. Cell Mol Life Sci 81(1):130","DOI":"10.1007\/s00018-024-05152-z"},{"issue":"1","key":"1570_CR61","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12882-025-04193-1","volume":"26","author":"A Gen\u00e7ler","year":"2025","unstructured":"Gen\u00e7ler A et al (2025) Hypoxia-inducible factor-1 alpha and nuclear factor erythroid 2-related factor 2 as biomarkers of renal scarring in children with congenital anomalies of the kidney and urinary tract: a prospective case-control study. BMC Nephrol 26(1):277","journal-title":"BMC Nephrol"},{"issue":"1","key":"1570_CR62","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41392-023-01651-w","volume":"8","author":"PD Talukdar","year":"2023","unstructured":"Talukdar PD, Chatterji U (2023) Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases. Signal Transduct Target Ther 8(1):427","journal-title":"Signal Transduct Target Ther"},{"key":"1570_CR63","unstructured":"Albanese A (2024) Deciphering the role of novel post-translation modifications found to occur during hypoxia signalling. University of Liverpool"},{"issue":"42","key":"1570_CR64","doi-asserted-by":"publisher","first-page":"35496","DOI":"10.1074\/jbc.M112.400697","volume":"287","author":"H Geng","year":"2012","unstructured":"Geng H et al (2012) HIF1\u03b1 protein stability is increased by acetylation at lysine 709 *. J Biol Chem 287(42):35496\u201335505","journal-title":"J Biol Chem"},{"key":"1570_CR65","doi-asserted-by":"crossref","unstructured":"Crawford CE, Burslem GM (2025) Acetylation: a new target for protein degradation in cancer. Trends in Cancer","DOI":"10.1016\/j.trecan.2025.01.013"},{"issue":"3","key":"1570_CR66","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/med.21774","volume":"41","author":"F Meng","year":"2021","unstructured":"Meng F et al (2021) Drug design targeting active posttranslational modification protein isoforms. Med Res Rev 41(3):1701\u20131750","journal-title":"Med Res Rev"},{"issue":"4","key":"1570_CR67","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1039\/D4CS00243A","volume":"4","author":"SP van Wier","year":"2025","unstructured":"van Wier SP, Beekman AM (2025) Peptide design to control protein\u2013protein interactions. Chem Soc Rev 4(4):1684\u20131698","journal-title":"Chem Soc Rev"},{"key":"1570_CR68","doi-asserted-by":"crossref","unstructured":"Li L, Liu S, Luo Y (2024) Application of covalent modality in proximity-induced drug pharmacology: early development, current strategy, and feature directions. Eur J Med Chem 116394.","DOI":"10.1016\/j.ejmech.2024.116394"},{"issue":"12","key":"1570_CR69","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1007\/s12033-023-00951-4","volume":"66","author":"SHA Raza","year":"2024","unstructured":"Raza SHA et al (2024) Advances of predicting allosteric mechanisms through protein contact in new technologies and their application. Mol Biotechnol 66(12):3385\u20133397","journal-title":"Mol Biotechnol"},{"issue":"3","key":"1570_CR70","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s11030-023-10650-6","volume":"28","author":"B Yazdani","year":"2024","unstructured":"Yazdani B et al (2024) Discovery of novel direct small-molecule inhibitors targeting HIF-2\u03b1 using structure-based virtual screening, molecular dynamics simulation, and MM-GBSA calculations. Mol Diversity 28(3):1203\u20131224","journal-title":"Mol Diversity"},{"issue":"1","key":"1570_CR71","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10555-023-10136-9","volume":"43","author":"S Fakhri","year":"2024","unstructured":"Fakhri S et al (2024) Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review. Cancer Metastasis Rev 43(1):501\u2013574","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"1570_CR72","doi-asserted-by":"publisher","first-page":"e62014","DOI":"10.1371\/journal.pone.0062014","volume":"8","author":"D Wu","year":"2013","unstructured":"Wu D et al (2013) A novel function of novobiocin: disrupting the interaction of HIF 1\u03b1 and p300\/CBP through direct binding to the HIF1\u03b1 C-terminal activation domain. PLoS ONE 8(5):e62014","journal-title":"PLoS ONE"},{"issue":"10","key":"1570_CR73","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41429-021-00451-0","volume":"74","author":"H Ikeda","year":"2021","unstructured":"Ikeda H, Kakeya H (2021) Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy. J Antibiot 74(10):687\u2013695","journal-title":"J Antibiot"},{"key":"1570_CR74","unstructured":"Karmazin A (2023) Heat-shock protein 90 (HSP90) in cell physiology"},{"key":"1570_CR75","unstructured":"Edmonds A (2022) The development of DUAL BRD4 and CBP\/p300 degraders from ISOX-DUAL. University of Sussex"},{"issue":"4","key":"1570_CR76","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/med.21948","volume":"43","author":"HL Ang","year":"2023","unstructured":"Ang HL et al (2023) Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds. Med Res Rev 43(4):1141\u20131200","journal-title":"Med Res Rev"},{"key":"1570_CR77","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-981-15-8473-2_13","volume-title":"role of signaling pathways in brain tumorigenesis","author":"MH Shahi","year":"2023","unstructured":"Shahi MH (2023) Role of HIF-1 in brain tumor development. role of signaling pathways in brain tumorigenesis. Springer, pp 155\u2013166"},{"issue":"7","key":"1570_CR78","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41419-024-06904-2","volume":"15","author":"J Bou-Gharios","year":"2024","unstructured":"Bou-Gharios J, No\u00ebl G, Burckel H (2024) Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme. Cell Death Dis 15(7):503","journal-title":"Cell Death Dis"},{"issue":"3","key":"1570_CR79","doi-asserted-by":"publisher","first-page":"168352","DOI":"10.1016\/j.jmb.2023.168352","volume":"436","author":"J Zhuang","year":"2024","unstructured":"Zhuang J et al (2024) Decoding allosteric control in hypoxia-inducible factors. J Mol Biol 436(3):168352","journal-title":"J Mol Biol"},{"key":"1570_CR80","doi-asserted-by":"crossref","unstructured":"Wang Z et al (2025) Cross-talk between WNT signaling and ferroptosis in cancer. Mol Cancer Res OF1-OF15","DOI":"10.1158\/1541-7786.MCR-24-0880"},{"key":"1570_CR81","doi-asserted-by":"publisher","first-page":"100302","DOI":"10.1016\/j.comtox.2024.100302","volume":"29","author":"SS Chauhan","year":"2024","unstructured":"Chauhan SS, Thaseen EA, Parthasarathi R (2024) Computational discovery of potent Escherichia coli DNA gyrase inhibitor: Selective and safer novobiocin analogues. Computational Toxicology 29:100302","journal-title":"Computational Toxicology"},{"key":"1570_CR82","doi-asserted-by":"publisher","first-page":"1384249","DOI":"10.3389\/fimmu.2024.1384249","volume":"15","author":"L Feldman","year":"2024","unstructured":"Feldman L (2024) Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments. Front Immunol 15:1384249","journal-title":"Front Immunol"},{"key":"1570_CR83","doi-asserted-by":"crossref","unstructured":"Bouleftour W et al (2021) Review of the role of hypoxia in radioresistance in cancer therapy. Med Sci Monit 3(27): e934116-1\u2013e934116-7","DOI":"10.12659\/MSM.934116"},{"key":"1570_CR84","doi-asserted-by":"publisher","first-page":"1435306","DOI":"10.3389\/fimmu.2024.1435306","volume":"15","author":"X Gong","year":"2024","unstructured":"Gong X et al (2024) The role of hypoxic microenvironment in autoimmune diseases. Front Immunol 15:1435306","journal-title":"Front Immunol"},{"issue":"8","key":"1570_CR85","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/ph17081048","volume":"17","author":"H Guo","year":"2024","unstructured":"Guo H et al (2024) The pivotal role of preclinical animal models in anti-cancer drug discovery and personalized cancer therapy strategies. Pharmaceuticals 17(8):1048","journal-title":"Pharmaceuticals"},{"key":"1570_CR86","doi-asserted-by":"publisher","first-page":"116492","DOI":"10.1016\/j.ejmech.2024.116492","volume":"273","author":"AM Said","year":"2024","unstructured":"Said AM et al (2024) Design, synthesis, molecular modeling, in vitro and in vivo biological evaluation of potent anthranilamide derivatives as dual P-glycoprotein and CYP3A4 inhibitors. Eur J Med Chem 273:116492","journal-title":"Eur J Med Chem"},{"issue":"8","key":"1570_CR87","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3390\/pharmaceutics16080974","volume":"16","author":"B Boersma","year":"2024","unstructured":"Boersma B, Poinot H, Pommier A (2024) Stimulating the antitumor immune response using immunocytokines: a preclinical and clinical overview. Pharmaceutics 16(8):974","journal-title":"Pharmaceutics"},{"key":"1570_CR88","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s13346-024-01754-z","volume":"15","author":"A Vikal","year":"2024","unstructured":"Vikal A et al (2024) Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions. Drug Deliv Transl Res 15:1801\u20131827","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"1570_CR89","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/therapeutics2010005","volume":"2","author":"S Karagil","year":"2025","unstructured":"Karagil S et al (2025) How natural therapies can combat neoplastic disease by targeting key survival mechanisms and signaling pathways. Therapeutics 2(1):5","journal-title":"Therapeutics"},{"issue":"19","key":"1570_CR90","doi-asserted-by":"publisher","first-page":"e70075","DOI":"10.1096\/fj.202401409R","volume":"38","author":"D Li","year":"2024","unstructured":"Li D, Geng D, Wang M (2024) Advances in natural products modulating autophagy influenced by cellular stress conditions and their anticancer roles in the treatment of ovarian cancer. FASEB J 38(19):e70075","journal-title":"FASEB J"},{"issue":"2","key":"1570_CR91","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/cancers13020188","volume":"13","author":"A Brockmueller","year":"2021","unstructured":"Brockmueller A et al (2021) Resveratrol\u2019s anti-cancer effects through the modulation of tumor glucose metabolism. Cancers 13(2):188","journal-title":"Cancers"},{"issue":"12","key":"1570_CR92","doi-asserted-by":"publisher","first-page":"6489","DOI":"10.1002\/ptr.7224","volume":"35","author":"BM Razavi","year":"2021","unstructured":"Razavi BM et al (2021) A review of therapeutic potentials of turmeric (Curcuma longa) and its active constituent, curcumin, oninflammatory disorders, pain, and their related patents. Phytother Res 35(12):6489\u20136513","journal-title":"Phytother Res"},{"key":"1570_CR93","first-page":"09141621","volume":"91","author":"C Tang","year":"2024","unstructured":"Tang C et al (2024) Curcumin and analogues as potential epigenetic modulators: prevention of metabolic diseases. ESS Open Archive eprints 91:09141621","journal-title":"ESS Open Archive eprints"},{"issue":"1","key":"1570_CR94","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/biom15010015","volume":"15","author":"G Casari","year":"2024","unstructured":"Casari G et al (2024) Epigenetic properties of compounds contained in functional foods against cancer. Biomolecules 15(1):15","journal-title":"Biomolecules"},{"issue":"6","key":"1570_CR95","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.3390\/ijms22062828","volume":"22","author":"P Kopytko","year":"2021","unstructured":"Kopytko P et al (2021) Garcinol\u2014a natural histone acetyltransferase inhibitor and new anti-cancer epigenetic drug. Int J Mol Sci 22(6):2828","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1570_CR96","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.3390\/cancers16112089","volume":"16","author":"E Begagi\u0107","year":"2024","unstructured":"Begagi\u0107 E et al (2024) Understanding the significance of hypoxia-inducible factors (HIFs) in glioblastoma: a systematic review. Cancers 16(11):2089","journal-title":"Cancers"},{"issue":"6","key":"1570_CR97","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.3390\/ijms25063313","volume":"25","author":"AG Magar","year":"2024","unstructured":"Magar AG et al (2024) A molecular perspective on HIF-1\u03b1 and angiogenic stimulator networks and their role in solid tumors: an update. Int J Mol Sci 25(6):3313","journal-title":"Int J Mol Sci"},{"key":"1570_CR98","doi-asserted-by":"publisher","first-page":"106828","DOI":"10.1016\/j.bpc.2022.106828","volume":"287","author":"S Rath","year":"2022","unstructured":"Rath S et al (2022) CTK7A, a curcumin derivative, can be a potential candidate for targeting HIF-1\u03b1\/p300 complex: Evidences from in vitro and computational studies. Biophys Chem 287:106828","journal-title":"Biophys Chem"},{"issue":"16","key":"1570_CR99","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.3390\/molecules27165192","volume":"27","author":"R Ghosh","year":"2022","unstructured":"Ghosh R et al (2022) Targeting HIF-1\u03b1 by natural and synthetic compounds: a promising approach for anti-cancer therapeutics development. Molecules 27(16):5192","journal-title":"Molecules"},{"issue":"1","key":"1570_CR100","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/cancers13010130","volume":"13","author":"M Samec","year":"2021","unstructured":"Samec M et al (2021) Flavonoids targeting HIF-1: implications on cancer metabolism. Cancers 13(1):130","journal-title":"Cancers"},{"issue":"12","key":"1570_CR101","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.2967\/jnumed.112.115436","volume":"54","author":"K-H Jung","year":"2013","unstructured":"Jung K-H et al (2013) Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species\u2013mediated hypoxia-inducible factor-1\u03b1 activation. J Nucl Med 54(12):2161\u20132167","journal-title":"J Nucl Med"},{"issue":"17","key":"1570_CR102","doi-asserted-by":"publisher","first-page":"6726","DOI":"10.7150\/thno.100667","volume":"14","author":"H Shen","year":"2024","unstructured":"Shen H et al (2024) Targeting sirtuins for cancer therapy: epigenetics modifications and beyond. Theranostics 14(17):6726","journal-title":"Theranostics"},{"issue":"4","key":"1570_CR103","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/cancers16040680","volume":"16","author":"NK Sharma","year":"2024","unstructured":"Sharma NK et al (2024) Understanding cancer\u2019s defense against topoisomerase-active drugs: a comprehensive review. Cancers 16(4):680","journal-title":"Cancers"},{"key":"1570_CR104","doi-asserted-by":"publisher","first-page":"106642","DOI":"10.1016\/j.bioorg.2023.106642","volume":"137","author":"L Wang","year":"2023","unstructured":"Wang L et al (2023) Natural epidithiodiketopiperazine alkaloids as potential anticancer agents: Recent mechanisms of action, structural modification, and synthetic strategies. Bioorg Chem 137:106642","journal-title":"Bioorg Chem"},{"key":"1570_CR105","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-031-75907-9_6","volume-title":"Clinical ophthalmic oncology: basic principles","author":"JH Joo","year":"2025","unstructured":"Joo JH, Rao S, Singh AD (2025) Cancer angiogenesis. Clinical ophthalmic oncology: basic principles. Springer, pp 51\u201371"},{"issue":"6","key":"1570_CR106","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1021\/cr500452k","volume":"115","author":"BM Dancy","year":"2015","unstructured":"Dancy BM, Cole PA (2015) Protein lysine acetylation by p300\/CBP. Chem Rev 115(6):2419\u20132452","journal-title":"Chem Rev"},{"key":"1570_CR107","doi-asserted-by":"publisher","first-page":"108636","DOI":"10.1016\/j.pharmthera.2024.108636","volume":"257","author":"M Strachowska","year":"2024","unstructured":"Strachowska M, Robaszkiewicz A (2024) Characteristics of anticancer activity of CBP\/p300 inhibitors\u2014features of their classes, intracellular targets and future perspectives of their application in cancer treatment. Pharmacol Therapeutics 257:108636","journal-title":"Pharmacol Therapeutics"},{"key":"1570_CR108","doi-asserted-by":"crossref","unstructured":"Liu B et al (2024) Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther 9(1):175","DOI":"10.1038\/s41392-024-01856-7"},{"key":"1570_CR109","doi-asserted-by":"crossref","unstructured":"Cecerska-Hery\u0107 E et al (2024) Can compounds of natural origin be important in chemoprevention? Anticancer properties of quercetin, resveratrol, and curcumin\u2014a comprehensive review. Int J Mol Sci 25(8):4505","DOI":"10.3390\/ijms25084505"},{"key":"1570_CR110","doi-asserted-by":"crossref","unstructured":"Qannita RA et al (2024) Targeting hypoxia-inducible factor-1 (HIF-1) in cancer: emerging therapeutic strategies and pathway regulation. Pharmaceuticals 17(2):195","DOI":"10.3390\/ph17020195"},{"key":"1570_CR111","doi-asserted-by":"crossref","unstructured":"Aljabali AA et al (2025) Natural anticancer drugs: efficacy, safety, and future challenges. Curr Med Chem 32(31):6764\u20136805","DOI":"10.2174\/0109298673344501250109210447"},{"key":"1570_CR112","doi-asserted-by":"crossref","unstructured":"Dom\u00e8nech M et al (2021) Hypoxia: the cornerstone of glioblastoma. Int J Mol Sci 22(22):12608","DOI":"10.3390\/ijms222212608"},{"issue":"2","key":"1570_CR113","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10522-025-10208-z","volume":"26","author":"R Thapa","year":"2025","unstructured":"Thapa R et al (2025) Hypoxia-inducible factor and cellular senescence in pulmonary aging and disease. Biogerontology 26(2):64","journal-title":"Biogerontology"},{"issue":"16","key":"1570_CR114","doi-asserted-by":"publisher","first-page":"12587","DOI":"10.3390\/ijms241612587","volume":"24","author":"NA Cacciola","year":"2023","unstructured":"Cacciola NA et al (2023) An overview of the enhanced effects of curcumin and chemotherapeutic agents in combined cancer treatments. Int J Mol Sci 24(16):12587","journal-title":"Int J Mol Sci"},{"key":"1570_CR115","doi-asserted-by":"publisher","first-page":"113072","DOI":"10.1016\/j.ejmech.2020.113072","volume":"210","author":"MS Hosseini-Zare","year":"2021","unstructured":"Hosseini-Zare MS et al (2021) Synergistic effects of curcumin and its analogs with other bioactive compounds: a comprehensive review. Eur J Med Chem 210:113072","journal-title":"Eur J Med Chem"},{"issue":"6","key":"1570_CR116","first-page":"1616","volume":"19","author":"M Zahedi","year":"2023","unstructured":"Zahedi M et al (2023) The effect of curcumin on hypoxia in the tumour microenvironment as a regulatory factor in cancer. Archives of Medical Science: AMS 19(6):1616","journal-title":"Archives of Medical Science: AMS"},{"issue":"3","key":"1570_CR117","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/ph18030286","volume":"18","author":"AJ Siddiqui","year":"2025","unstructured":"Siddiqui AJ et al (2025) Therapeutic potential of plant-and marine-derived bioactive compounds in prostate cancer: mechanistic insights and translational applications. Pharmaceuticals 18(3):286","journal-title":"Pharmaceuticals"},{"issue":"4","key":"1570_CR118","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.7150\/thno.92526","volume":"14","author":"X-J Dai","year":"2024","unstructured":"Dai X-J et al (2024) Degraders in epigenetic therapy: PROTACs and beyond. Theranostics 14(4):1464","journal-title":"Theranostics"},{"issue":"12","key":"1570_CR119","doi-asserted-by":"publisher","first-page":"e2409685122","DOI":"10.1073\/pnas.2409685122","volume":"122","author":"S Dhungel","year":"2025","unstructured":"Dhungel S et al (2025) Structural assembly of the PAS domain drives the catalytic activation of metazoan PASK. Proc Natl Acad Sci 122(12):e2409685122","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1570_CR120","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z et al (2023) Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8(1):70","journal-title":"Signal Transduct Target Ther"},{"key":"1570_CR121","doi-asserted-by":"crossref","unstructured":"Zhang T-Q et al (2024) The cellular-centered view of hypoxia tumor microenvironment: molecular mechanisms and therapeutic interventions. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1879(5): 189137","DOI":"10.1016\/j.bbcan.2024.189137"},{"key":"1570_CR122","doi-asserted-by":"crossref","unstructured":"Amin N et al (2024) The Janus face of HIF-1\u03b1 in ischemic stroke and the possible associated pathways. Neurochem Int 177:105747","DOI":"10.1016\/j.neuint.2024.105747"},{"key":"1570_CR123","unstructured":"Nandi I (2024) Cellular and metabolic reprogramming in breast Cancer and its therapeutic implications. McGill University (Canada)"},{"key":"1570_CR124","doi-asserted-by":"crossref","unstructured":"Bailey CM et al (2022) Targeting HIF-1\u03b1 abrogates PD-L1\u2013mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. J Clin Investig 132(9):e150846","DOI":"10.1172\/JCI150846"},{"key":"1570_CR125","doi-asserted-by":"crossref","unstructured":"Ultimo A et al (2025) Nanotherapeutic formulations for the delivery of cancer antiangiogenics. Mol Pharm 22(5):2322\u20132349","DOI":"10.1021\/acs.molpharmaceut.4c00822"},{"key":"1570_CR126","doi-asserted-by":"crossref","unstructured":"Wang X et al (2024) Effects of natural products on angiogenesis in melanoma. Fitoterapia 177:106100","DOI":"10.1016\/j.fitote.2024.106100"},{"key":"1570_CR127","doi-asserted-by":"crossref","unstructured":"Eubank TD et al (2024) In vivo electron paramagnetic resonance molecular profiling of tumor microenvironment upon tumor progression to malignancy in an animal model of breast cancer. Mol Imag Biol 26(3):424\u2013434","DOI":"10.1007\/s11307-023-01847-0"},{"key":"1570_CR128","doi-asserted-by":"crossref","unstructured":"Zhou Y et al (2023) Experimental mouse models for translational human cancer research. Front Immunol 14:1095388","DOI":"10.3389\/fimmu.2023.1095388"},{"key":"1570_CR129","doi-asserted-by":"crossref","unstructured":"Li X et al (2023) New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis. Biomed Pharmacother 163:114806","DOI":"10.1016\/j.biopha.2023.114806"},{"key":"1570_CR130","doi-asserted-by":"crossref","unstructured":"Albini A et al (2024) The past and future of angiogenesis as a target for cancer therapy and prevention. Cancer Prev Res 17(7):289\u2013303","DOI":"10.1158\/1940-6207.CAPR-24-0085"},{"key":"1570_CR131","doi-asserted-by":"crossref","unstructured":"Richters A, Koehler AN (2017) Epigenetic modulation using small molecules-targeting histone acetyltransferases in disease. Curr Med Chem 24(37):4121\u20134150","DOI":"10.2174\/0929867324666170223153115"},{"key":"1570_CR132","doi-asserted-by":"crossref","unstructured":"Jackson W III et al (2024) Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy. Sci Adv 10(35):eadq2366","DOI":"10.1126\/sciadv.adq2366"},{"key":"1570_CR133","doi-asserted-by":"crossref","unstructured":"Yuan X et al (2024) Targeting hypoxia-inducible factors: therapeutic opportunities and challenges. Nat Rev Drug Discovery 23(3):175\u2013200","DOI":"10.1038\/s41573-023-00848-6"},{"key":"1570_CR134","doi-asserted-by":"crossref","unstructured":"Ma S et al (2021) As a biomarker for gastric cancer, circPTPN22 regulates the progression of gastric cancer through the EMT pathway. Cancer Cell Int 21:1\u201314","DOI":"10.1186\/s12935-020-01701-1"},{"key":"1570_CR135","unstructured":"DeJohn C (2023) Noninvasive imaging of the immune-vascular crosstalk in head and neck cancer. State University of New York at Buffalo"},{"key":"1570_CR136","doi-asserted-by":"crossref","unstructured":"Bellissimo CJ et al (2024) Maternal high-fat, high-sucrose diet-induced excess adiposity is linked to placental hypoxia and disruption of fetoplacental immune homeostasis in late gestation. bioRxiv 2024.09. 30.615691","DOI":"10.1101\/2024.09.30.615691"},{"key":"1570_CR137","doi-asserted-by":"crossref","unstructured":"Hirota K (2021) HIF-\u03b1 prolyl hydroxylase inhibitors and their implications for biomedicine: a comprehensive review. Biomedicines 9(5):468","DOI":"10.3390\/biomedicines9050468"},{"key":"1570_CR138","doi-asserted-by":"crossref","unstructured":"Weng L et al (2025) Hypoxia-targeted responsive delivery of doxorubicin and digoxin for synergistic treatment of triplenegative breast cancer. Mol Pharm 22(4):2142\u20132158","DOI":"10.1021\/acs.molpharmaceut.4c01325"},{"key":"1570_CR139","doi-asserted-by":"crossref","unstructured":"Ganesh MS, Revanth R, Bharathi CME (2025) Advanced biomarkers and precision medicine: innovative strategies to prevent cancer recurrence. J Cancer Res Updates 14:1\u201311","DOI":"10.30683\/1929-2279.2025.14.01"},{"key":"1570_CR140","doi-asserted-by":"crossref","unstructured":"Subbaiah MA, Rautio J, Meanwell NA (2024) Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates. Chem Soc Rev 53(4):2099\u20132210","DOI":"10.1039\/D2CS00957A"},{"key":"1570_CR141","doi-asserted-by":"crossref","unstructured":"Wang S et al (2022) Nanoparticle-based medicines in clinical cancer therapy. Nano Today 45:101512","DOI":"10.1016\/j.nantod.2022.101512"},{"key":"1570_CR142","doi-asserted-by":"crossref","unstructured":"Yang M et al (2024) Harnessing nanotechnology: emerging strategies for multiple myeloma therapy. Biomolecules 14(1):83","DOI":"10.3390\/biom14010083"},{"issue":"3","key":"1570_CR143","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.3289","volume":"116","author":"K Rowland Yeo","year":"2024","unstructured":"Rowland Yeo K, Gil Berglund E, Chen Y (2024) Dose optimization informed by PBPK modeling: state-of-the art and future. Clin Pharmacol Ther 116(3):563\u2013576","journal-title":"Clin Pharmacol Ther"},{"key":"1570_CR144","doi-asserted-by":"crossref","unstructured":"Harkos C et al (2025) Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer. Nat Rev Cancer 25:324\u2013340","DOI":"10.1038\/s41568-025-00796-w"},{"issue":"11","key":"1570_CR145","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.3390\/ijms25115667","volume":"25","author":"T Watabe","year":"2024","unstructured":"Watabe T et al (2024) Preclinical evaluation of biodistribution and toxicity of [211At]PSMA-5 in mice and primates for the targeted alpha therapy against prostate cancer. Int J Mol Sci 25(11):5667","journal-title":"Int J Mol Sci"},{"key":"1570_CR146","doi-asserted-by":"crossref","unstructured":"Nordgren IK, Tavassoli A (2011) Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor. Chem Soc Rev 40(8):4307\u20134317","DOI":"10.1039\/c1cs15032d"},{"issue":"4","key":"1570_CR147","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/17435390.2024.2361687","volume":"18","author":"LY Li","year":"2024","unstructured":"Li LY et al (2024) Evaluation of the biodistribution and preliminary safety profile of a novel brain-targeted manganese dioxide-based nanotheranostic system for Alzheimer\u2019s disease. Nanotoxicology 18(4):315\u2013334","journal-title":"Nanotoxicology"},{"key":"1570_CR148","doi-asserted-by":"publisher","first-page":"117955492412985","DOI":"10.1177\/11795549241298541","volume":"18","author":"M AlDoughaim","year":"2024","unstructured":"AlDoughaim M et al (2024) Cancer biomarkers and precision oncology: a review of recent trends and innovations. Clin Med Insights: Oncol 18:11795549241298540","journal-title":"Clin Med Insights: Oncol"},{"issue":"2","key":"1570_CR149","first-page":"100937","volume":"17","author":"M Houshyari","year":"2024","unstructured":"Houshyari M (2024) A critical review on exploring tumor microenvironment\u2019s impacts on radioresistance. J Radiat Res Appl Sci 17(2):100937","journal-title":"J Radiat Res Appl Sci"},{"issue":"5","key":"1570_CR150","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","volume":"130","author":"FR Weth","year":"2024","unstructured":"Weth FR et al (2024) Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. Br J Cancer 130(5):703\u2013715","journal-title":"Br J Cancer"},{"issue":"1","key":"1570_CR151","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13148-025-01844-w","volume":"17","author":"A Tahghighi","year":"2025","unstructured":"Tahghighi A et al (2025) Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies. Clin Epigenetics 17(1):34","journal-title":"Clin Epigenetics"},{"key":"1570_CR152","unstructured":"Beckers C (2024) Targeting survival pathways to overcome hypoxia-driven radioresistance. University of Zurich"},{"issue":"5","key":"1570_CR153","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/ijms26051839","volume":"26","author":"J Wu","year":"2025","unstructured":"Wu J et al (2025) Radioresistance in hepatocellular carcinoma: biological bases and therapeutic implications. Int J Mol Sci 26(5):1839","journal-title":"Int J Mol Sci"},{"key":"1570_CR154","doi-asserted-by":"publisher","first-page":"116783","DOI":"10.1016\/j.biopha.2024.116783","volume":"176","author":"M Yang","year":"2024","unstructured":"Yang M et al (2024) Survival strategies: how tumor hypoxia microenvironment orchestrates angiogenesis. Biomed Pharmacother 176:116783","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"1570_CR155","first-page":"571","volume":"21","author":"J Mou","year":"2024","unstructured":"Mou J et al (2024) Research progress in tumor angiogenesis and drug resistance in breast cancer. Cancer Biol Med 21(7):571\u2013585","journal-title":"Cancer Biol Med"},{"key":"1570_CR156","doi-asserted-by":"publisher","first-page":"1344272","DOI":"10.3389\/fimmu.2024.1344272","volume":"15","author":"P Ouyang","year":"2024","unstructured":"Ouyang P et al (2024) Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors. Front Immunol 15:1344272","journal-title":"Front Immunol"},{"issue":"12","key":"1570_CR157","doi-asserted-by":"publisher","first-page":"e2502597122","DOI":"10.1073\/pnas.2502597122","volume":"122","author":"C Yan","year":"2025","unstructured":"Yan C, Wang X-F (2025) Tumor immune evasion: systemic immunosuppressive networks beyond the local microenvironment. Proc Natl Acad Sci 122(12):e2502597122","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1570_CR158","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C (2025) Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer 24(1):5","journal-title":"Mol Cancer"},{"key":"1570_CR159","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.2147\/IJN.S505539","volume":"20","author":"Y Ge","year":"2025","unstructured":"Ge Y et al (2025) Utilizing nanoparticles to overcome anti-PD-1\/PD-L1 immunotherapy resistance in non-small cell lung cancer: a potential strategy. Int J Nanomed 20:2371\u20132394","journal-title":"Int J Nanomed"},{"key":"1570_CR160","doi-asserted-by":"publisher","first-page":"117257","DOI":"10.1016\/j.biopha.2024.117257","volume":"178","author":"Q Tang","year":"2024","unstructured":"Tang Q et al (2024) Reprogramming of glucose metabolism: the hallmark of malignant transformation and target for advanced diagnostics and treatments. Biomed Pharmacother 178:117257","journal-title":"Biomed Pharmacother"},{"key":"1570_CR161","doi-asserted-by":"publisher","first-page":"122890","DOI":"10.1016\/j.lfs.2024.122890","volume":"352","author":"N Taneja","year":"2024","unstructured":"Taneja N et al (2024) HIF-1 mediated metabolic reprogramming in cancer: mechanisms and therapeutic implications. Life Sci 352:122890","journal-title":"Life Sci"},{"issue":"7","key":"1570_CR162","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.7150\/jca.92502","volume":"15","author":"H Zhang","year":"2024","unstructured":"Zhang H et al (2024) Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: combining radiotherapy and metabolic targeting therapy. J Cancer 15(7):2003","journal-title":"J Cancer"},{"issue":"5","key":"1570_CR163","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/diseases12050093","volume":"12","author":"P Mohanty","year":"2024","unstructured":"Mohanty P et al (2024) Unravelling the triad of lung cancer, drug resistance, and metabolic pathways. Diseases 12(5):93","journal-title":"Diseases"},{"key":"1570_CR164","unstructured":"Thornton L (2023) Investigating the role of eIF4A2 in the spatial regulation of metabolic adaptation to hypoxia in colorectal cancer. University of Nottingham"},{"issue":"2","key":"1570_CR165","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41591-023-02784-9","volume":"30","author":"M Moqri","year":"2024","unstructured":"Moqri M et al (2024) Validation of biomarkers of aging. Nat Med 30(2):360\u2013372","journal-title":"Nat Med"},{"key":"1570_CR166","doi-asserted-by":"crossref","unstructured":"Czerwinski A et al (2025) Stub1 acetylation by CBP\/p300 attenuates chronic hypoxic-driven pulmonary hypertension by suppressing HIF-2\u03b1. Am J Respir Cell Mol Biol (ja)","DOI":"10.1165\/rcmb.2024-0353OC"},{"key":"1570_CR167","doi-asserted-by":"crossref","unstructured":"Calatayud DG et al (2022) Nano-theranostics for the sensing, imaging and therapy of prostate cancers. Front Chem 10:830133","DOI":"10.3389\/fchem.2022.830133"},{"key":"1570_CR168","unstructured":"Angel Z (2020) Regulation of microRNA expression in prostate cancer by hypoxia. Ulster University"},{"key":"1570_CR169","doi-asserted-by":"publisher","first-page":"100174","DOI":"10.1016\/j.medidd.2023.100174","volume":"21","author":"D Chen","year":"2024","unstructured":"Chen D (2024) Biomarkers navigate drug development: pharmacology, effectiveness and safety. Med Drug Discovery 21:100174","journal-title":"Med Drug Discovery"},{"issue":"21","key":"1570_CR170","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.3390\/cancers16213564","volume":"16","author":"AA Dominguez","year":"2024","unstructured":"Dominguez AA et al (2024) Unveiling the promise: navigating clinical trials 1978\u20132024 for PDAC. Cancers 16(21):3564","journal-title":"Cancers"},{"key":"1570_CR171","doi-asserted-by":"crossref","unstructured":"Bhattacharjee R et al (2022) Theragnostic strategies harnessing the self-renewal pathways of stem-like cells in the acute myeloid leukemia. Crit Rev Oncol Hematol 177:103753","DOI":"10.1016\/j.critrevonc.2022.103753"},{"issue":"4","key":"1570_CR172","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/biomedicines11041060","volume":"11","author":"A Mussa","year":"2023","unstructured":"Mussa A et al (2023) The NF-\u03baB transcriptional network is a high-dose vitamin C-targetable vulnerability in breast cancer. Biomedicines 11(4):1060","journal-title":"Biomedicines"},{"key":"1570_CR173","unstructured":"Zaidi M (2024) Exploring microenvironmental heterogeneity in cancer and renal biology through spatial transcriptomics and multiplexed immunohistochemistry. University of Toronto (Canada)"},{"key":"1570_CR174","doi-asserted-by":"crossref","unstructured":"Bhattacharya S et al (2025) Advancements in cancer research: exploring diagnostics and therapeutic breakthroughs. Bentham Science Publishers","DOI":"10.2174\/97898153059061250101"},{"issue":"1","key":"1570_CR175","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/JCO.2005.01.072","volume":"23","author":"D Rischin","year":"2005","unstructured":"Rischin D et al (2005) Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02). J Clin Oncol 23(1):79\u201387","journal-title":"J Clin Oncol"},{"key":"1570_CR176","doi-asserted-by":"crossref","unstructured":"Cutsem EV et al (2016) MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 34(15_suppl):4007\u20134007","DOI":"10.1200\/JCO.2016.34.15_suppl.4007"},{"key":"1570_CR177","doi-asserted-by":"crossref","unstructured":"Chan KH et al (2024) Belzutifan, HIF-2\u03b1 inhibitor, and clear cell renal cell carcinoma with somatic Von-Hippel-Lindau loss-of-function mutation. J Investig Med High Impact Case Rep 12:23247096241231640","DOI":"10.1177\/23247096241231641"},{"key":"1570_CR178","doi-asserted-by":"crossref","unstructured":"Choi WW et al (2023) Belzutifan (MK-6482): biology and clinical development in solid tumors. Curr Oncol Rep 25(2):123\u2013129","DOI":"10.1007\/s11912-022-01354-5"},{"key":"1570_CR179","doi-asserted-by":"crossref","unstructured":"Gallez B (2022) The role of imaging biomarkers to guide pharmacological interventions targeting tumor hypoxia. Front Pharmacol13 - 2022","DOI":"10.3389\/fphar.2022.853568"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01570-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01570-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01570-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:31Z","timestamp":1760195011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01570-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":179,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01570-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}